Cabozantinib after immunotherapy in advanced kidney cancer

This recent retrospective study included 84 patients with metastatic renal cell carcinoma (RCC) who were treated with cabozantinib after being treated with nivolumab. Most of the patients had poor- or intermediate-risk RCC and all patients received a tyrosine kinase inhibitor (TKI) as first-line therapy, followed by nivolumab in the second- or third-line. Median progression-free survival […]

read more

Axitinib effective as a third-line treatment for kidney cancer

A recent study published in the journal In Vivo assessed the therapeutic effect of axitinib as a third-line therapy following second-line nivolumab monotherapy in patients with metastatic renal cell carcinoma (RCC). Data from patients treated with axitinib as a third-line therapy after failure of first-line tyrosine kinase inhibitor (TKI) and second-line nivolumab monotherapy were reviewed. […]

read more
Showing all 2 results
  TOP